Showing results (51-60 of 1,068) with videos related to
Sort By:
Pageof 107
Journal of Pharmacokinetics and Pharmacodynamics|April 2, 2010
Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlationJae Eun Ahn, Jonathan L FrenchJournal of Pharmacokinetics and Pharmacodynamics|August 5, 2009
Performance in population models for count data, part I: maximum likelihood approximationsElodie L Plan, Alan Maloney, Iñaki F Trocóniz, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 4, 2009
Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximationsHans Peter GrimmJournal of Pharmacokinetics and Pharmacodynamics|April 24, 2020
Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacyAnil R Maharaj, Huali Wu, Christoph P Hornik, et al.Journal of Pharmacokinetics and Pharmacodynamics|April 27, 2020
A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosusSonja Hartmann, Konstantinos Biliouris, Himanshu Naik, et al.Journal of Pharmacokinetics and Pharmacodynamics|April 15, 2020
A longitudinal item response model for Aberrant Behavior Checklist (ABC) data from children with autismElham Haem, Marziyeh Doostfatemeh, Negar Firouzabadi, et al.Journal of Pharmacokinetics and Pharmacodynamics|August 30, 2025
APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer's Disease: A mixed-effects disease progression modelCarson Essenburg, Murali RamanathanJournal of Pharmacokinetics and Pharmacodynamics|May 25, 2021
A latent variable approach to account for correlated inputs in global sensitivity analysisNicola Melillo, Adam S DarwichJournal of Pharmacokinetics and Pharmacodynamics|June 6, 2020
Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modelingShihao Hu, David Z D'ArgenioJournal of Pharmacokinetics and Pharmacodynamics|August 11, 2021
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseasesPeter Bloomingdale, Suruchi Bakshi, Christian Maass, et al.Pageof 107